Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: J Rheumatol)
Source: J Rheumatol - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
PanAmerican League of Associations for Rheumatology Recommendations for the Treatment of Psoriatic Arthritis
CONCLUSION: Herein, we present a set of recommendations to guide decision-making in treatment of PsA in America, based on the best evidence available, considering resources, medical expertise, and patient's values and preferences. The successful implementation of these recommendations should be based on clinical practice conditions, health care setting on each country, and tailored evaluation of patients.PMID:38561190 | DOI:10.3899/jrheum.2023-1172 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Daniel G Fern ández-Ávila Wilson Bautista-Molano Mar ía Lorena Brance Mar ía Gabriela Ávila Pedretti Rub én Burgos Vargas Jos é Francisco Díaz Coto Luis Arturo Guti érrez Marwin Guti érrez Enrique Giraldo Ho Sebasti án Eduardo Ibáñez Vodnizza Source Type: research
Patients with psoriatic arthritis-related enthesitis are more likely to persist on tofacitinib under real-life conditions
CONCLUSION: In this real-life study, tofacitinib showed a reasonably good retention rate in a PsA population mostly refractory to biologic and oral targeted-synthetic DMARDs. Patients with refractory PsA and enthesitis might be a specific target population for this drug. No new alarm signals emerged.PMID:38561189 | DOI:10.3899/jrheum.2024-0016 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 1, 2024 Category: Rheumatology Authors: Ignacio Bra ña Marta Loredo Estefan ía Pardo Stefanie Burger Eva Fern ández-Bretón Rub én Queiro Source Type: research
